Oragenics Inc. (OGEN)
| Market Cap | 77.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.43M |
| Shares Out | 56.53M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $0.711 |
| Previous Close | $0.697 |
| Change ($) | 0.014 |
| Change (%) | 2.02% |
| Day's Open | 0.670 |
| Day's Range | 0.630 - 0.727 |
| Day's Volume | 4,173,684 |
| 52-Week Range | 0.372 - 2.090 |
Oragenics Inc (NYSE: OGEN) stock is soaring higher after announcing a deal related to its Terra CoV-2 vaccine candidate against COVID-19. Oragenics has reached an agreement with Biodextris that will all...
Oragenics (OGEN) stock is soaring higher on Tuesday after announcing a deal concerning its vaccine candidate for the novel coronavirus. The post OGEN Stock: Why Shares of Biotech Oragenics Are Skyrocket...
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics to Participate in Two Investment Conferences During March
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock
SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice
TAMPA, Fla.--(BUSINESS WIRE)--SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice
Oragenics (OGEN) stock is soaring higher on Thursday from new coronavirus vaccine news after just receiving a boost last week. The post OGEN Stock Alert: Why Oragenics Shares Are Flying Again Thursday a...
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Issues Letter to Stockholders
Oragenics (OGEN) is seeing shares of OGEN stock take off on Thursday on a news update for its vaccine to treat the novel coronavirus. The post OGEN Stock Alert: 14 Things to Know About Oragenics as Shar...
TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS ENTERS INTO MATERIAL TRANSFER AGREEMENT WITH ADJUVANCE TECHNOLOGIES FOR COVID-19 VACCINE ADJUVANT
TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS ANNOUNCES CLOSING OF $6.5 MILLION REGISTERED DIRECT OFFERING
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. Announces $6.5 Million Registered Direct Offering
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Closing of $6.0 Million Underwritten Public Offering
TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS PRICES $5.25 MILLION COMMON STOCK OFFERING
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Proposed Underwritten Public Offering
Oragenics is planning to launch clinical trials of its coronavirus vaccine in early 2021. OGEN stock is soaring on the news.
TAMPA, Fla.--(BUSINESS WIRE)--FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccine
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Inc.
TAMPA, Fla. & TUSTIN, Calif.
TAMPA, Fla.--(BUSINESS WIRE)--Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies
About OGEN
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. Its product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. The compan... [Read more...]
| Industry Biotechnology | Founded 1996 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol OGEN |